Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

Background/Aims: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671)....

Full description

Bibliographic Details
Main Authors: Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M. Robinson, Roopal B. Thakkar, Toshifumi Hibi
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2017-07-01
Series:Intestinal Research
Subjects:
Biological products
Endoscopy
Ulcer
Behçet's disease, intestinal
Online Access:https://doi.org/10.5217/ir.2017.15.3.395

Internet

https://doi.org/10.5217/ir.2017.15.3.395

Similar Items